Overview

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

Status:
Unknown status

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare how safe, tolerable, and effective a novel drug, raltegravir, is to a commonly used combination, atazanavir/ritonavir, as initial treatment in HIV/Hepatitis C co-infected injecting drug users on a methadone program.

Phase:

Phase 4

Details

Lead Sponsor:

St. James's Hospital, Ireland

Treatments:

Atazanavir Sulfate
HIV Protease Inhibitors
Methadone
Protease Inhibitors
Raltegravir Potassium
Ritonavir